Approval for the ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD (BVS) System.  This device is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions >=2.5 mm to <=3.75 mm in diameter in lesions <=24 mm in length.